Giulia Angela Carla Pattarino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giulia Angela Carla Pattarino has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Romandini
Clinical Pharmacology Unit, Chemical-Clinical Analyses Laboratory, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications - Chiara Resnati
Clinical Pharmacology Unit, Chemical-Clinical Analyses Laboratory, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications - Costantino De Giacomo
Division of Pediatrics, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications - Elena Altieri
Division of Pediatrics, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications - Romano Danesi
Clinical Pharmacology Unit, Chemical-Clinical Analyses Laboratory, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications - Stefania Crucitta
Clinical Pharmacology Unit, Chemical-Clinical Analyses Laboratory, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 883
Stewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness for Recently Approved Antibiotics in Pediatric Practice
The rise of multidrug-resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling is often deferred due to the complexities of developmental pharmacology and due to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of the most recent antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, and ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting lipoglycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of antimicrobial stewardship through the “3 D’s” rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety controls to proactive, model-informed precision dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.
- 9 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 883
Open AccessStewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness for Recently Approved Antibiotics in Pediatric Practice
The rise of multidrug-resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling is often deferred due to the complexities of developmental pharmacology and due to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of the most recent antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, and ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting lipoglycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of antimicrobial stewardship through the “3 D’s” rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety controls to proactive, model-informed precision dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.
- Open Access
- 30 July 2026
- Published by MDPI AG in Preprints.org
Stewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness of Recently Approved Antibiotics in Pediatric Practice
The rise of multi-drug resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling often lags due to the complexities of developmental pharmacology and to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of "new" antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting glycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of Antimicrobial Stewardship through the "3 Ds" rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety checks to proactive, Model-Informed Precision Dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.
- 30 July 2026
- Published by MDPI AG in Preprints.org
Open AccessStewardship Challenges, PK/PD Evidence, and Prescribing Appropriateness of Recently Approved Antibiotics in Pediatric Practice
The rise of multi-drug resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling often lags due to the complexities of developmental pharmacology and to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of "new" antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting glycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of Antimicrobial Stewardship through the "3 Ds" rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety checks to proactive, Model-Informed Precision Dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.